Active surveillance for low risk papillary thyroid cancer

We read with interest the article published by Akira Miyauchi, “Clinical Trials of Active Surveillance of Papillary Microcarcinoma of Thyroid” in the World Journal of Surgery [2016] (1), which summarizes 22 years of experience with this approach. Dr. Miyauchi, who is the father of active surveillance (AS) for low risk thyroid cancer, concludes that, “although we still offer two options, immediate surgery or observation, to patients with low risk papillary micro-carcinoma (PMC) at Kuma Hospital, we now strongly recommend observation as the best choice.”